WO1998039027A3 - Sialyl lewis antigens as targets for immunotherapy - Google Patents

Sialyl lewis antigens as targets for immunotherapy Download PDF

Info

Publication number
WO1998039027A3
WO1998039027A3 PCT/US1998/004314 US9804314W WO9839027A3 WO 1998039027 A3 WO1998039027 A3 WO 1998039027A3 US 9804314 W US9804314 W US 9804314W WO 9839027 A3 WO9839027 A3 WO 9839027A3
Authority
WO
WIPO (PCT)
Prior art keywords
antigens
cancers
melanoma
immunotherapy
targets
Prior art date
Application number
PCT/US1998/004314
Other languages
French (fr)
Other versions
WO1998039027A2 (en
Inventor
Mepur H Ravindranath
Donald L Morton
Original Assignee
Wayne John Cancer Inst
Mepur H Ravindranath
Donald L Morton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wayne John Cancer Inst, Mepur H Ravindranath, Donald L Morton filed Critical Wayne John Cancer Inst
Priority to AU65428/98A priority Critical patent/AU6542898A/en
Publication of WO1998039027A2 publication Critical patent/WO1998039027A2/en
Publication of WO1998039027A3 publication Critical patent/WO1998039027A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Abstract

Sialyls Lewis (sLe) antigens are functionally important, immunogenic, tumorigenic or differentiation antigens and potential targets for both passive and active specific immunotherapy of melanoma and other cancers sharing these antigens. The present invention concerns the use of such antigens in vaccine formulations for the treatment of a variety of cancers and in particular melanoma. The B lymphocytes from the vaccine recipients will be used to harvest human monoclonal antibodies and use it as a drug for treatment of melanoma and other cancers.
PCT/US1998/004314 1997-03-05 1998-03-05 Sialyl lewis antigens as targets for immunotherapy WO1998039027A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU65428/98A AU6542898A (en) 1997-03-05 1998-03-05 Sialyl lewis antigens as targets for immunotherapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81128197A 1997-03-05 1997-03-05
US08/811,281 1997-03-05

Publications (2)

Publication Number Publication Date
WO1998039027A2 WO1998039027A2 (en) 1998-09-11
WO1998039027A3 true WO1998039027A3 (en) 1999-01-07

Family

ID=25206107

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/004314 WO1998039027A2 (en) 1997-03-05 1998-03-05 Sialyl lewis antigens as targets for immunotherapy

Country Status (2)

Country Link
AU (1) AU6542898A (en)
WO (1) WO1998039027A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9475874B2 (en) 2013-08-26 2016-10-25 MabVax Therapeutics, Inc. Nucleic acids encoding human antibodies to sialyl-lewisa

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002045740A1 (en) * 2000-12-08 2002-06-13 Children's Memorial Hospital Compositions containing gangliosides for use in the treatment of skin disorders
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
EP1417965A1 (en) * 2002-11-07 2004-05-12 Vereniging Voor Christelijk Wetenschappelijk Onderwijs C-type lectin binding molecules, identification and uses thereof
JP4942664B2 (en) 2005-02-01 2012-05-30 モーフォシス アーゲー Libraries and methods for isolating antibodies
FR2919804B1 (en) * 2007-08-08 2010-08-27 Erytech Pharma COMPOSITION AND ANTI-TUMOR THERAPEUTIC VACCINE
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof
US10384796B2 (en) * 2012-04-04 2019-08-20 Commercial Aerospace Plane Pty Limited Aerospace plane system
US11613759B2 (en) 2015-09-04 2023-03-28 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
WO2018102682A1 (en) 2016-12-01 2018-06-07 Regeneron Pharmaceuticals, Inc. Radiolabeled anti-pd-l1 antibodies for immuno-pet imaging

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0508282A2 (en) * 1991-04-01 1992-10-14 Kyowa Hakko Kogyo Co., Ltd. Anti-idiotypic monoclonal antibodies
WO1992022565A1 (en) * 1991-06-10 1992-12-23 Alberta Research Council Modified sialyl lewisx compounds
WO1997027872A1 (en) * 1996-01-31 1997-08-07 President And Fellows Of Harvard College Immunomodulatory methods using oligosaccharides

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0508282A2 (en) * 1991-04-01 1992-10-14 Kyowa Hakko Kogyo Co., Ltd. Anti-idiotypic monoclonal antibodies
WO1992022565A1 (en) * 1991-06-10 1992-12-23 Alberta Research Council Modified sialyl lewisx compounds
WO1997027872A1 (en) * 1996-01-31 1997-08-07 President And Fellows Of Harvard College Immunomodulatory methods using oligosaccharides

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CANCER IMMUNOLOGY, IMMUNOTHERAPY, (1998 FEB) 45 (6) 281-6 *
CANCER, (1997 MAY 1) 79 (9) 1686-97 *
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; KIEBER-EMMONS T ET AL: "Peptide mimicry of adenocarcinoma-associated carbohydrate antigens.", XP002083156 *
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; KUDRYASHOV V ET AL: "Immunogenicity of synthetic conjugates of Lewis(y) oligosaccharide with proteins in mice: towards the design of anticancer vaccines.", XP002083157 *
DATABASE MEDLINE US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; RAVINDRANATH M H ET AL: "Endothelial-selectin ligands sialyl Lewis (x) and sialyl Lewis (a) are differentiation antigens immunogenic in human melanoma.", XP002083158 *
HYBRIDOMA, (1997 FEB) 16 (1) 3-10 *
MAKINO K ET AL: "Expression of tumor-associated glycoantigen, sialyl Lewis (a), in human head and neck squamous cell carcinoma and its application to tumor immunotherapy.", JAPANESE JOURNAL OF CANCER RESEARCH, (1994 SEP) 85 (9) 887-91, XP002083154 *
RAVINDRANATH M H ET AL: "Ratio of IgG:IgM antibodies to sialyl Lewis (x) and GM3 correlates with tumor growth after immunization with melanoma-cell vaccine with different adjuvants in mice.", INTERNATIONAL JOURNAL OF CANCER, (1998 JAN 5) 75 (1) 117-24, XP002083155 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9475874B2 (en) 2013-08-26 2016-10-25 MabVax Therapeutics, Inc. Nucleic acids encoding human antibodies to sialyl-lewisa

Also Published As

Publication number Publication date
WO1998039027A2 (en) 1998-09-11
AU6542898A (en) 1998-09-22

Similar Documents

Publication Publication Date Title
WO1999002550A8 (en) Ctl epitopes from ebv
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
HK1097449A1 (en) Methods for in vivo delivery of biologics and compositions useful therefor
EP1203817A3 (en) Compounds and methods for immunotherapy and diagnosis of tuberculosis
AU7980794A (en) Methods and compositions for microencapsulation of antigens for use as vaccines
HK1028548A1 (en) Formulations for hydrophobic pharmaceutical agents
CA2381770A1 (en) Human ctla-4 antibodies and their uses
WO2002072636A8 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
MY125202A (en) Vaccine
WO1998053075A3 (en) Compounds for immunotherapy and diagnosis of tuberculosis and methods of their use
WO1998033527A3 (en) Cancer immunotherapy with semi-allogeneic cells
WO2000018351A3 (en) Aglyco products and methods of use
EP1731166A3 (en) Streptococcus pneumoniae proteins and vaccines
WO1998039027A3 (en) Sialyl lewis antigens as targets for immunotherapy
AU6832398A (en) Multiple antigen glycopeptide carbohydrate, vaccine comprising the same and use thereof
WO2005007673A3 (en) Immunogenic peptides
CA2232344A1 (en) Compositions and methods for enhancing immune responses mediated by antigen-presenting cells
DK0845998T3 (en) Immunotherapy drugs containing antibodies that specifically recognize the MHCII antigen in a patient to be treated
EP0770624A3 (en) Peptide capable of inducing immune response to human gastric cancer and agent containing it for preventing or treating human gastric cancer
WO2000055194A3 (en) Tuberculosis antigens and methods of use therefor
WO2000052045A3 (en) Mage-3 derived immunogenic peptides presented by mhc of class ii and the use thereof
EP1801123A3 (en) Crystals of whole antibodies and fragments thereof and methods for making and using them
WO2003093298A3 (en) Immunogenic peptides
WO2000001729A3 (en) Synthetic peptides and pharmaceutical compositions comprising them for diagnosis and treatment of anti-phospholipid syndrome
BR9915071A (en) Use of an enterobacterium ompa protein or one of its fragments

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: JP

Ref document number: 1998538807

Format of ref document f/p: F

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA